 |
|
New Developments in the Treatment of Psoriasis
Arch Dermatol. 2002;138:686-688.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
THE ABILITY to create custom-made drugs that target specific cell receptors
or specific cytokines is heralding a new era in the treatment of inflammatory
diseases. This is particularly relevant for psoriasis because the agents that
have been developed block specific steps in the pathogenesis of this disease.
In this issue of the ARCHIVES, Singri and coauthors1
present an excellent mechanism-oriented description of the new biologic therapies
emerging for treatment of psoriasis.
Recognizing that the skin changes in psoriasis are easily evaluated,
many of the pharmaceutical companies have chosen to test their drugs in psoriasis
at an early stage in the evolution of these therapies. Before enthusiastically
embracing these exciting new therapeutic modalities, an important question
must be asked: Do we really need more psoriasis treatments?
THE IDEAL PSORIASIS THERAPY
Over the past 25 years, probably more treatments have been developed
for psoriasis than for any other skin disorder. Not even counting the many
topical . . . [Full Text of this Article]
SAFETY AND EFFICACY OF NEW BIOLOGIC AGENTS FOR PSORIASIS
THE IDEAL PATIENT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Biologic Therapy for Psoriasis: The New Therapeutic Frontier
Prashant Singri, Dennis P. West, and Kenneth B. Gordon
Arch Dermatol. 2002;138(5):657-663.
ABSTRACT
| FULL TEXT
|
